AGIOS PHARMACEUTICALS, INC.
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is a commercial-stage biopharmaceutical company dedicated to developing innovative medicines for rare diseases, with a primary focus on classical hematology and cellular metabolism. The company's website is www.agios.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What AGIOS PHARMACEUTICALS, INC. does
In the company’s own words
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is a commercial-stage biopharmaceutical company dedicated to developing innovative medicines for rare diseases, with a primary focus on classical hematology and cellular metabolism. The company's website is www.agios.com.
Agios markets two FDA-approved products based on its lead compound mitapivat, a pyruvate kinase activator. PYRUKYND® treats hemolytic anemia in adults with pyruvate kinase deficiency and has received approvals in the European Union and Great Britain for the same indication. AQVESME™, approved in December 2025, treats anemia in adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia in the United States and represents the only FDA-approved medicine for anemia in both forms of thalassemia. The company also markets PYRUKYND® in Saudi Arabia for thalassemia treatment and maintains a global managed access program for eligible patients in other jurisdictions.
Beyond its approved products, Agios maintains a pipeline of clinical-stage candidates. Tebapivat, a novel pyruvate kinase activator, is in development for lower-risk myelodysplastic syndromes and sickle cell disease. The company is evaluating mitapivat for pediatric pyruvate kinase deficiency and sickle cell disease, with plans to submit a U.S. marketing application for the latter following a pre-supplemental New Drug Application meeting in the first quarter of 2026. Additionally, Agios is developing AG-181, a phenylalanine hydroxylase stabilizer for phenylketonuria treatment, and AG-236, an siRNA targeting the TMPRSS6 gene for polycythemia vera, which was in-licensed from Alnylam Pharmaceuticals in July 2023.
The company previously divested its oncology business to Servier Pharmaceuticals in March 2021 and subsequently sold royalty rights related to vorasidenib to Royalty Pharma in August 2024, generating significant non-operating income. Agios maintains full ownership of its hematology franchise and has established commercial infrastructure in the United States while entering into distribution agreements with NewBridge Pharmaceuticals for the Gulf Cooperation Council region and Avanzanite Bioscience for the European Economic Area, Switzerland, and the United Kingdom.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1439222
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns AGIOS PHARMACEUTICALS, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · AGIOS PHARMACEUTICALS, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do AGIOS PHARMACEUTICALS, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of AGIOS PHARMACEUTICALS, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in AGIOS PHARMACEUTICALS, INC.'s last four quarterly filings that the numbers alone won't show?”